SAB Biotherapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-06-01

Employees: 57

Market Cap: -

Website: http://www.sab.bio

Clinical Trials

Active:0

Completed:3

Trial Phases

2 Phases

Phase 1:4

Phase 2:1

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1

4 (80.0%)

Phase 2

1 (20.0%)

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

Phase 1

Recruiting

Conditions: PHA1A

Interventions: Drug: Single Ascending Dose of SAB-176
Drug: Single Ascending Dose of Placebo

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: SAb Biotherapeutics, Inc.

Target Recruit Count: 35

Registration Number: NCT06435936

Locations: 🇺🇸
Naval Medical Research Command (NMRC), Bethesda, Maryland, United States

Study of SAB-176 in Healthy Adult Participants

Phase 2

Completed

Conditions: Influenza A H1N1

Interventions: Biological: SAB-176
Other: Placebo

First Posted Date: 2021-04-20

Last Posted Date: 2025-01-22

Lead Sponsor: SAb Biotherapeutics, Inc.

Target Recruit Count: 62

Registration Number: NCT04850898

Locations: 🇬🇧
Queen Mary BioEnterprises Innovation Centre, London, United Kingdom

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Phase 1

Completed

Conditions: Influenza Type B
Influenza Type A
Influenza

Interventions: Biological: SAB-176
Other: Normal Saline

First Posted Date: 2020-07-14

Last Posted Date: 2025-01-06

Lead Sponsor: SAb Biotherapeutics, Inc.

Target Recruit Count: 27

Registration Number: NCT04471038

Locations: 🇺🇸
PPD, Phase 1 Clinic, Austin, Texas, United States

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

Phase 1

Completed

Conditions: COVID-19
SARS-CoV2

First Posted Date: 2020-07-13

Last Posted Date: 2022-07-01

Lead Sponsor: SAb Biotherapeutics, Inc.

Target Recruit Count: 28

Registration Number: NCT04468958

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

Phase 1

Conditions: COVID-19
SARS-CoV2

First Posted Date: 2020-07-13

Last Posted Date: 2021-10-26

Lead Sponsor: SAb Biotherapeutics, Inc.

Target Recruit Count: 21

Registration Number: NCT04469179

Locations: 🇺🇸
Quantum Clinical Trials, Miami Beach, Florida, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States

News

Influenza Pipeline Surges with 120+ Therapies as Moderna, AstraZeneca Lead Innovation Wave

5 days ago

The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies.